Decode News AI
简体繁體

Servier Reports Four-Year Clinical Results for Tovorafenib in Pediatric Brain Cancer

2026-11-15 14:46 EST · AI-compiled · 272 words · about 1 min · Views …
Photo: AI 生成配图

BOSTON - Servier Pharmaceuticals announced updated four-year follow-up results on Nov. 14. The data come from its Phase 2 FIREFLY-1 trial of tovorafenib in pediatric low-grade glioma.

试验数据在年会上公布

Clinical oncology investigators presented the multi-year study data at the 2026 Society for Neuro-Oncology Annual Meeting in Boston. The trial evaluated tovorafenib, an oral type II RAF kinase inhibitor. It enrolled patients aged six months to 25 years with relapsed or refractory BRAF-altered pediatric brain tumors. Results showed sustained disease control and manageable safety profiles.

四年观察期内肿瘤保持稳定

Patients maintained durable tumor stabilization across four years of exploratory clinical observation. Researchers confirmed no cumulative bone marrow or developmental growth toxicities emerged during long-term therapy. Patients kept up regular school attendance during ongoing treatment cycles.

儿童低级别胶质瘤的治疗负担

Pediatric low-grade glioma is the most prevalent pediatric central nervous system tumor. Conventional systemic chemotherapy frequently causes permanent cognitive and physical complications in young children. "For children and families living with pediatric low-grade glioma, time spent off treatment is meaningful," Duke Cancer Institute investigator Daniel Landi confirmed during the clinical session. Extended disease control without debilitating toxicity gives clinicians reliable evidence to optimize personalized long-term cancer care protocols.

确证性试验与申报计划

Servier is completing global patient recruitment for its confirmatory Phase 3 FIREFLY-2 front-line study. That trial compares tovorafenib with standard chemotherapy. The pharmaceutical company plans to submit marketing authorization applications to the European Medicines Agency throughout 2027.

后续发表与影响

Clinical investigators plan to publish comprehensive four-year progression data in peer-reviewed pediatric oncology medical journals early next year. Oncology researchers anticipate that these findings will accelerate pediatric drug evaluations and broaden targeted treatment options globally.

Sources

Found a factual error or typo? Tell us

Follow Decode News AI on Telegram

Live updates: every new story is pushed the moment it publishes — dozens a day, no digest delay.

@decodenewsai · Subscribe now

Free · unsubscribe anytime

Comments